PROF

Company Overview — What Does Profound Medical Corp. Do?

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada. Profound Medical Corp. (PROF) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Arun S. Menawat and employs approximately 150 people. With a market capitalization of $237M, PROF is one of the notable companies in the Healthcare sector.

Profound Medical Corp. (PROF) Stock Rating — Reduce (April 2026)

As of April 2026, Profound Medical Corp. receives a Reduce rating with a composite score of 36.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PROF ranks #3,815 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Profound Medical Corp. ranks #643 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PROF Stock Price and 52-Week Range

Profound Medical Corp. (PROF) currently trades at $6.44. The 52-week high for PROF is $8.95, which means the stock is currently trading -28.0% from its annual peak. The 52-week low is $3.76, putting the stock 71.3% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is PROF Overvalued or Undervalued? — Valuation Analysis

Profound Medical Corp. (PROF) carries a value factor score of 20/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 4.57x, compared to the Healthcare sector average of 23.63x — a discount of 81%. The price-to-book ratio stands at 3.49x, versus the sector average of 2.75x. The price-to-sales ratio is 3.60x, compared to 1.66x for the average Healthcare stock.

At current multiples, Profound Medical Corp. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Profound Medical Corp. Profitability — ROE, Margins, and Quality Score

Profound Medical Corp. (PROF) earns a quality factor score of 30/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -256.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -219.8% versus the sector average of -33.1%.

On a margin basis, Profound Medical Corp. reports gross margins of 70.8%, compared to 71.5% for the sector. The operating margin is -256.3% (sector: -66.1%). Net profit margin stands at -264.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 86.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PROF Debt, Balance Sheet, and Financial Health

Profound Medical Corp. has a debt-to-equity ratio of 7.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 12.52x, indicating strong short-term liquidity. Total debt on the balance sheet is $4M. Cash and equivalents stand at $25M.

PROF has a beta of 0.88, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Profound Medical Corp. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Profound Medical Corp. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Profound Medical Corp. reported revenue of $16M and earnings per share (EPS) of $1.41. Net income for the quarter was $-43M. Gross margin was 70.8%. Operating income came in at $-41M.

In FY 2025, Profound Medical Corp. reported revenue of $16M and earnings per share (EPS) of $1.41. Net income for the quarter was $-43M. Gross margin was 70.8%. Revenue grew 50.7% year-over-year compared to FY 2024. Operating income came in at $-41M.

In Q3 2025, Profound Medical Corp. reported revenue of $5M and earnings per share (EPS) of $0.26. Net income for the quarter was $-8M. Gross margin was 74.3%. Operating income came in at $-9M.

In Q2 2025, Profound Medical Corp. reported revenue of $2M and earnings per share (EPS) of $0.52. Net income for the quarter was $-16M. Gross margin was 73.2%. Operating income came in at $-14M.

Over the past 8 quarters, Profound Medical Corp. has demonstrated a growth trajectory, with revenue expanding from $7M to $16M. Investors analyzing PROF stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PROF Dividend Yield and Income Analysis

Profound Medical Corp. (PROF) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PROF Momentum and Technical Analysis Profile

Profound Medical Corp. (PROF) has a momentum factor score of 47/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.

PROF vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Profound Medical Corp. (PROF) ranks #643 out of 838 stocks based on the Blank Capital composite score. This places PROF in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PROF against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PROF vs S&P 500 (SPY) comparison to assess how Profound Medical Corp. stacks up against the broader market across all factor dimensions.

PROF Next Earnings Date

No upcoming earnings date has been announced for Profound Medical Corp. (PROF) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PROF? — Investment Thesis Summary

The quantitative profile for Profound Medical Corp. suggests caution. The quality score of 30/100 flags below-average profitability. The value score of 20/100 indicates premium valuation. High volatility (stability score 35/100) increases portfolio risk.

In summary, Profound Medical Corp. (PROF) earns a Reduce rating with a composite score of 36.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PROF stock.

Related Resources for PROF Investors

Explore more research and tools: PROF vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PROF head-to-head with peers: PROF vs AZN, PROF vs SLGL, PROF vs VMD.